Emily Roarty

2.7k total citations
24 papers, 480 citations indexed

About

Emily Roarty is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Emily Roarty has authored 24 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Emily Roarty's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Emily Roarty is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Emily Roarty collaborates with scholars based in United States and Israel. Emily Roarty's co-authors include John V. Heymach, Stephen G. Swisher, Jianjun Zhang, J. Jack Lee, Lara Lacerda, William N. William, Marcelo F. Benveniste, Waree Rinsurongkawong, Gustavo Schvartsman and S. Andrew Peng and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Annals of Thoracic Surgery.

In The Last Decade

Emily Roarty

23 papers receiving 478 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emily Roarty United States	10	348	330	138	79	54	24	480
Cláudia Casanova Italy	9	273 0.8×	267 0.8×	128 0.9×	100 1.3×	30 0.6×	24	421
Maria Bassanelli Italy	10	419 1.2×	326 1.0×	68 0.5×	99 1.3×	57 1.1×	23	547
L. Bouhlel France	5	530 1.5×	397 1.2×	161 1.2×	52 0.7×	80 1.5×	7	621
Greg Andrew Durm United States	11	375 1.1×	324 1.0×	56 0.4×	97 1.2×	60 1.1×	52	488
M-J. Ahn South Korea	14	517 1.5×	394 1.2×	93 0.7×	118 1.5×	105 1.9×	68	622
Beung‐Chul Ahn South Korea	12	497 1.4×	366 1.1×	81 0.6×	106 1.3×	106 2.0×	38	621
M.V. Bluthgen France	8	243 0.7×	238 0.7×	180 1.3×	98 1.2×	28 0.5×	18	424
Chester Kao United States	8	164 0.5×	160 0.5×	108 0.8×	110 1.4×	43 0.8×	19	330
Yunjian Huang China	9	217 0.6×	182 0.6×	73 0.5×	65 0.8×	48 0.9×	30	345
Chukwuemeka Ikpeazu United States	9	189 0.5×	144 0.4×	65 0.5×	119 1.5×	44 0.8×	23	356

Countries citing papers authored by Emily Roarty

Since Specialization

Citations

This map shows the geographic impact of Emily Roarty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Roarty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Roarty more than expected).

Fields of papers citing papers by Emily Roarty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Roarty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Roarty. The network helps show where Emily Roarty may publish in the future.

Co-authorship network of co-authors of Emily Roarty

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Roarty. A scholar is included among the top collaborators of Emily Roarty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Roarty. Emily Roarty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lam, Vincent K., Jianjun Zhang, Carol C. Wu, et al.. (2020). Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. Journal of Thoracic Oncology. 16(4). 601–609. 58 indexed citations

Ruiz‐Cordero, Roberto, Junsheng Ma, Abha Khanna, et al.. (2020). Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer. 20(1). 83–83. 14 indexed citations

Williams, Loretta A., Qiuling Shi, Seyedeh Dibaj, et al.. (2019). MA19.03 Differences in Symptom Burden Between Responsive and Progressive Disease in Advanced Non-Small Cell Lung Cancer (aNSCLC). Journal of Thoracic Oncology. 14(10). S327–S327. 1 indexed citations

Negrão, Marcelo V., Vincent K. Lam, Alexandre Reuben, et al.. (2019). PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(6). 1021–1031. 69 indexed citations

Negrão, Marcelo V., Victoria M. Raymond, Richard B. Lanman, et al.. (2019). Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.. Journal of Clinical Oncology. 37(15_suppl). 3102–3102. 1 indexed citations

Mitchell, K. G., Marcelo V. Negrão, Edwin R. Parra, et al.. (2019). Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. The Annals of Thoracic Surgery. 109(2). 358–366. 9 indexed citations

Hong, Lingzhi, Seyedeh Dibaj, Marcelo V. Negrão, et al.. (2019). Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 37(15_suppl). 9017–9017. 10 indexed citations

Williams, Loretta A., Shiva Dibaj, Sheenu Chandwani, et al.. (2018). P3.01-109 Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S907–S908. 1 indexed citations

Negrão, Marcelo V., Alexandre Reuben, Jacqulyne Robichaux, et al.. (2018). P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S733–S734. 2 indexed citations

10.

Chandwani, Sheenu, Seyedeh Dibaj, Emily Roarty, et al.. (2018). P3.01-91 Computing the Impact of Immunotherapy on the Non-Small Cell Lung Cancer (NSCLC) Therapeutic Landscape. Journal of Thoracic Oncology. 13(10). S901–S902. 1 indexed citations

11.

Elamin, Yasir Y., Daniel R. Gomez, Mara B. Antonoff, et al.. (2018). Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small-cell Lung Cancer (NSCLC). Clinical Lung Cancer. 20(1). 43–47. 44 indexed citations

12.

Lam, Vincent K., Hai T. Tran, Kimberly C. Banks, et al.. (2018). Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. Clinical Lung Cancer. 20(1). 30–36.e3. 32 indexed citations

13.

Le, Xiuning, Sonam Puri, Marcelo V. Negrão, et al.. (2018). Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.. Journal of Clinical Oncology. 36(15_suppl). 9087–9087. 3 indexed citations

14.

Guijarro, Irene, Alissa Poteete, Renata Ferrarotto, et al.. (2017). P2.03a-048 The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth. Journal of Thoracic Oncology. 12(1). S918–S918. 1 indexed citations

15.

Elamin, Yasir Y., Waree Rinsurongkawong, Hai T. Tran, et al.. (2017). MA14.03 The Impact of Genomic Landscape of EGFR Mutant NSCLC on Response to Targeted and Immune Therapy. Journal of Thoracic Oncology. 12(1). S423–S424. 1 indexed citations

16.

Skoulidis, Ferdinandos, Yasir Y. Elamin, Vassiliki A. Papadimitrakopoulou, et al.. (2017). MA04.07 Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy. Journal of Thoracic Oncology. 12(1). S361–S362. 7 indexed citations

17.

Schvartsman, Gustavo, S. Andrew Peng, J. Jack Lee, et al.. (2017). Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer. 112. 90–95. 161 indexed citations

18.

Schvartsman, Gustavo, S. Andrew Peng, J. Jack Lee, et al.. (2017). Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 35(15_suppl). 9083–9083. 2 indexed citations

19.

Sepesi, Boris, Lara Lacerda, Jianjun Zhang, et al.. (2017). Immunogenomic profiling of non-small cell lung cancer: The ICON project.. Journal of Clinical Oncology. 35(15_suppl). e20034–e20034.

20.

Guijarro, Irene, Warren L. Denning, Renata Ferrarotto, et al.. (2016). The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells.. Journal of Clinical Oncology. 34(15_suppl). e20099–e20099. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact